SS
DNA icon

Steve Schonfeld’s Ginkgo Bioworks DNA Stock Holding History

Steve Schonfeld’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-169,710
Closed -$967K – 2147
2025
Q1 		$967K Buy
169,710
+67,829
+67% +$691K 0.01% 1316
2024
Q4 		$1M Buy
+101,881
New +$873K 0.01% 1120
2024
Q3 		– Sell
-14,449
Closed -$193K – 2120
2024
Q2 		$193K Buy
14,449
+12,600
+681% +$376K ﹤0.01% 1819
2024
Q1 		$85.8K Buy
+1,849
New +$95.7K ﹤0.01% 1866
2023
Q2 		– Sell
-498
Closed -$26.5K – 2217
2023
Q1 		$26.5K Sell
498
-13,372
-96% -$847K ﹤0.01% 1817
2022
Q4 		$938K Buy
13,870
+556
+4% +$51.1K 0.01% 1184
2022
Q3 		$1.66M Buy
13,314
+5,009
+60% +$597K 0.01% 968
2022
Q2 		$790K Buy
8,305
+6,800
+452% +$829K 0.01% 1127
2022
Q1 		$243K Buy
+1,505
New +$293K ﹤0.01% 1820

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steve Schonfeld's DNA Position: Q2 2025 in Review

Steve Schonfeld sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 169,710 shares — an estimated $967K sold.

Steve Schonfeld first reported a position in DNA in Q1 2022 and held it in 9 quarters. The position peaked at $1.66M in Q3 2022. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

  • Steve Schonfeld reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
  • Steve Schonfeld sold 169,710 Ginkgo Bioworks shares in Q2 2025, an estimated $967K.
  • Steve Schonfeld first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 9 quarters.
  • Steve Schonfeld's Ginkgo Bioworks position peaked at $1.66M in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.